Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C

Calogero Cammà, Savino Bruno, Vito Di Marco, Danilo Di Bona, Mariagrazia Rumi, Maria Vinci, Chiara Rebucci, Agostino Cividini, Giuseppe Pizzolanti, Ernesto Minola, Mario U. Mondelli, Massimo Colombo, Giovanbattista Pinzello, Antonio Craxì

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

Conflicting data exist regarding the relationship between hepatitis C virus genotype 1 and hepatic steatosis as well as the latter's role in the progression of fib rosis and treatment response. We assessed factors associated with hepatic steatosis in genotype 1 chronic hepatitis C and the impact of hepatic fat on fibrosis development and interferon responsiveness. Two hundred ninety-one non-diabetic patients with genotype 1 chronic hepatitis C were examined for the presence of steatosis and its correlation with clinical, virological, and biochemical data, including insulin resistance (IR), evaluated by the homeostasis model assessment (HOMA) score. Steatosis was graded as mild (1%-20% of hepatocytes involved), moderate (21%-40% of hepatocytes involved), and severe (>40% of hepatocytes involved). Steatosis was mild in 110 of 291 (37.8%) and moderate/severe in 55 of 291 (18.9%) subjects. By logistic regression, moderate/severe steatosis was independently associated with the female sex (odds ratio [OR] 2.74; 95% CI 1.40-5.35), high γ- glutamyltransferase levels (OR 1.52; 95% CI 1.22-1.91), and HOMA-score (OR 1.076; 95% CI 1.001-1.26). By logistic regression, moderate/severe steatosis (OR 2.78; 95% CI 1.21-6.4), and platelet counts (OR 0.97; 95% CI 0.96-0.98) were independent predictors of advanced fibrosis. Patients with moderate/severe steatosis had an OR of 0.52 (95% CI 0.30-0.90) for sustained virological response compared with patients with mild/absent steatosis. In conclusion, in nondiabetic European patients with genotype 1 hepatitis C at low risk for the metabolic syndrome, the prevalence of steatosis was nearly 60%. IR is a risk factor for moderate/severe steatosis, especially in men. Moderate/severe steatosis has clinical relevance, being associated with advanced fibrosis and hyporesponsiveness to antiviral therapy.

Original languageEnglish
Pages (from-to)64-71
Number of pages8
JournalHepatology
Volume43
Issue number1
DOIs
Publication statusPublished - Jan 2006

Fingerprint

Chronic Hepatitis C
Insulin Resistance
Odds Ratio
Genotype
Hepatocytes
Fibrosis
Liver
Homeostasis
Logistic Models
Sex Ratio
Hepatitis C
Platelet Count
Hepacivirus
Interferons
Antiviral Agents
Fats
Therapeutics

ASJC Scopus subject areas

  • Hepatology

Cite this

Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. / Cammà, Calogero; Bruno, Savino; Di Marco, Vito; Di Bona, Danilo; Rumi, Mariagrazia; Vinci, Maria; Rebucci, Chiara; Cividini, Agostino; Pizzolanti, Giuseppe; Minola, Ernesto; Mondelli, Mario U.; Colombo, Massimo; Pinzello, Giovanbattista; Craxì, Antonio.

In: Hepatology, Vol. 43, No. 1, 01.2006, p. 64-71.

Research output: Contribution to journalArticle

Cammà, C, Bruno, S, Di Marco, V, Di Bona, D, Rumi, M, Vinci, M, Rebucci, C, Cividini, A, Pizzolanti, G, Minola, E, Mondelli, MU, Colombo, M, Pinzello, G & Craxì, A 2006, 'Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C', Hepatology, vol. 43, no. 1, pp. 64-71. https://doi.org/10.1002/hep.20983
Cammà, Calogero ; Bruno, Savino ; Di Marco, Vito ; Di Bona, Danilo ; Rumi, Mariagrazia ; Vinci, Maria ; Rebucci, Chiara ; Cividini, Agostino ; Pizzolanti, Giuseppe ; Minola, Ernesto ; Mondelli, Mario U. ; Colombo, Massimo ; Pinzello, Giovanbattista ; Craxì, Antonio. / Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. In: Hepatology. 2006 ; Vol. 43, No. 1. pp. 64-71.
@article{89193bae5d7d42aab4ee1366a8ca215c,
title = "Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C",
abstract = "Conflicting data exist regarding the relationship between hepatitis C virus genotype 1 and hepatic steatosis as well as the latter's role in the progression of fib rosis and treatment response. We assessed factors associated with hepatic steatosis in genotype 1 chronic hepatitis C and the impact of hepatic fat on fibrosis development and interferon responsiveness. Two hundred ninety-one non-diabetic patients with genotype 1 chronic hepatitis C were examined for the presence of steatosis and its correlation with clinical, virological, and biochemical data, including insulin resistance (IR), evaluated by the homeostasis model assessment (HOMA) score. Steatosis was graded as mild (1{\%}-20{\%} of hepatocytes involved), moderate (21{\%}-40{\%} of hepatocytes involved), and severe (>40{\%} of hepatocytes involved). Steatosis was mild in 110 of 291 (37.8{\%}) and moderate/severe in 55 of 291 (18.9{\%}) subjects. By logistic regression, moderate/severe steatosis was independently associated with the female sex (odds ratio [OR] 2.74; 95{\%} CI 1.40-5.35), high γ- glutamyltransferase levels (OR 1.52; 95{\%} CI 1.22-1.91), and HOMA-score (OR 1.076; 95{\%} CI 1.001-1.26). By logistic regression, moderate/severe steatosis (OR 2.78; 95{\%} CI 1.21-6.4), and platelet counts (OR 0.97; 95{\%} CI 0.96-0.98) were independent predictors of advanced fibrosis. Patients with moderate/severe steatosis had an OR of 0.52 (95{\%} CI 0.30-0.90) for sustained virological response compared with patients with mild/absent steatosis. In conclusion, in nondiabetic European patients with genotype 1 hepatitis C at low risk for the metabolic syndrome, the prevalence of steatosis was nearly 60{\%}. IR is a risk factor for moderate/severe steatosis, especially in men. Moderate/severe steatosis has clinical relevance, being associated with advanced fibrosis and hyporesponsiveness to antiviral therapy.",
author = "Calogero Camm{\`a} and Savino Bruno and {Di Marco}, Vito and {Di Bona}, Danilo and Mariagrazia Rumi and Maria Vinci and Chiara Rebucci and Agostino Cividini and Giuseppe Pizzolanti and Ernesto Minola and Mondelli, {Mario U.} and Massimo Colombo and Giovanbattista Pinzello and Antonio Crax{\`i}",
year = "2006",
month = "1",
doi = "10.1002/hep.20983",
language = "English",
volume = "43",
pages = "64--71",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C

AU - Cammà, Calogero

AU - Bruno, Savino

AU - Di Marco, Vito

AU - Di Bona, Danilo

AU - Rumi, Mariagrazia

AU - Vinci, Maria

AU - Rebucci, Chiara

AU - Cividini, Agostino

AU - Pizzolanti, Giuseppe

AU - Minola, Ernesto

AU - Mondelli, Mario U.

AU - Colombo, Massimo

AU - Pinzello, Giovanbattista

AU - Craxì, Antonio

PY - 2006/1

Y1 - 2006/1

N2 - Conflicting data exist regarding the relationship between hepatitis C virus genotype 1 and hepatic steatosis as well as the latter's role in the progression of fib rosis and treatment response. We assessed factors associated with hepatic steatosis in genotype 1 chronic hepatitis C and the impact of hepatic fat on fibrosis development and interferon responsiveness. Two hundred ninety-one non-diabetic patients with genotype 1 chronic hepatitis C were examined for the presence of steatosis and its correlation with clinical, virological, and biochemical data, including insulin resistance (IR), evaluated by the homeostasis model assessment (HOMA) score. Steatosis was graded as mild (1%-20% of hepatocytes involved), moderate (21%-40% of hepatocytes involved), and severe (>40% of hepatocytes involved). Steatosis was mild in 110 of 291 (37.8%) and moderate/severe in 55 of 291 (18.9%) subjects. By logistic regression, moderate/severe steatosis was independently associated with the female sex (odds ratio [OR] 2.74; 95% CI 1.40-5.35), high γ- glutamyltransferase levels (OR 1.52; 95% CI 1.22-1.91), and HOMA-score (OR 1.076; 95% CI 1.001-1.26). By logistic regression, moderate/severe steatosis (OR 2.78; 95% CI 1.21-6.4), and platelet counts (OR 0.97; 95% CI 0.96-0.98) were independent predictors of advanced fibrosis. Patients with moderate/severe steatosis had an OR of 0.52 (95% CI 0.30-0.90) for sustained virological response compared with patients with mild/absent steatosis. In conclusion, in nondiabetic European patients with genotype 1 hepatitis C at low risk for the metabolic syndrome, the prevalence of steatosis was nearly 60%. IR is a risk factor for moderate/severe steatosis, especially in men. Moderate/severe steatosis has clinical relevance, being associated with advanced fibrosis and hyporesponsiveness to antiviral therapy.

AB - Conflicting data exist regarding the relationship between hepatitis C virus genotype 1 and hepatic steatosis as well as the latter's role in the progression of fib rosis and treatment response. We assessed factors associated with hepatic steatosis in genotype 1 chronic hepatitis C and the impact of hepatic fat on fibrosis development and interferon responsiveness. Two hundred ninety-one non-diabetic patients with genotype 1 chronic hepatitis C were examined for the presence of steatosis and its correlation with clinical, virological, and biochemical data, including insulin resistance (IR), evaluated by the homeostasis model assessment (HOMA) score. Steatosis was graded as mild (1%-20% of hepatocytes involved), moderate (21%-40% of hepatocytes involved), and severe (>40% of hepatocytes involved). Steatosis was mild in 110 of 291 (37.8%) and moderate/severe in 55 of 291 (18.9%) subjects. By logistic regression, moderate/severe steatosis was independently associated with the female sex (odds ratio [OR] 2.74; 95% CI 1.40-5.35), high γ- glutamyltransferase levels (OR 1.52; 95% CI 1.22-1.91), and HOMA-score (OR 1.076; 95% CI 1.001-1.26). By logistic regression, moderate/severe steatosis (OR 2.78; 95% CI 1.21-6.4), and platelet counts (OR 0.97; 95% CI 0.96-0.98) were independent predictors of advanced fibrosis. Patients with moderate/severe steatosis had an OR of 0.52 (95% CI 0.30-0.90) for sustained virological response compared with patients with mild/absent steatosis. In conclusion, in nondiabetic European patients with genotype 1 hepatitis C at low risk for the metabolic syndrome, the prevalence of steatosis was nearly 60%. IR is a risk factor for moderate/severe steatosis, especially in men. Moderate/severe steatosis has clinical relevance, being associated with advanced fibrosis and hyporesponsiveness to antiviral therapy.

UR - http://www.scopus.com/inward/record.url?scp=33644806684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644806684&partnerID=8YFLogxK

U2 - 10.1002/hep.20983

DO - 10.1002/hep.20983

M3 - Article

VL - 43

SP - 64

EP - 71

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -